Nonsteroidal anti-inflammatory drug (NSAID) that inhibits γ-secretase activity. Selectively lowers Aβ42 levels in human neuroglioma cells; displays no effect on Aβ40 levels at a concentration of 100 μM.
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 244.26. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||4.09 mL||20.47 mL||40.94 mL|
|5 mM||0.82 mL||4.09 mL||8.19 mL|
|10 mM||0.41 mL||2.05 mL||4.09 mL|
|50 mM||0.08 mL||0.41 mL||0.82 mL|
The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.
References are publications that support the products' biological activity.
Eriksen et al (2003) NSAIDs and enantiomers of flurbiprofen target γ-secretase and lower Aβ42 in vivo. J.Clin.Invest. 112 440 PMID: 12897211
Kukar et al (2007) Chronic administration of R-flurbiprofen attenuates learning impairments in transgenic amyloid precursor protein mice. BMC Neurosci. 8 54 PMID: 17650315
If you know of a relevant reference for Flurizan, please let us know.
View Related Products by Product Action
Keywords: NSAIDs gamma secretase inhibitors inhibits AB42 beta amyloid flurbiprofen tarenflurbil R-flurbiprofen Aβ42 and Abeta42 gamma-secretase amyloidbeta amyloidb amyloidβ (R)-Flurbiprofen Gamma-Secretase
Citations for Flurizan
Citations are publications that use Tocris products.
Currently there are no citations for Flurizan. Do you know of a great paper that uses Flurizan from Tocris? If so please let us know.
Literature in this Area
Alzheimer's disease (AD) is a degenerative brain disease and the most common cause of dementia, affecting approximately 47 million people worldwide. Updated in 2015, this poster summarizes the structural and functional changes observed in the progression of this neurodegenerative disease, as well as classic AD drug targets.